Modulating Effect of Peptide Therapy on the Morphofunctional State of Bronchial Epithelium in Rats with Obstructive Lung Pathology.
Bronchogen therapy showed potential in reversing structural changes in the bronchial epithelium in a rat model of COPD, but further studies are needed to confirm its relevance in humans.
Where it sits
this study against the rest of the bronchogen (aedl) corpusSummary and findings
The study investigated the effect of the tetrapeptide Bronchogen on the bronchial epithelium in a rat model of chronic obstructive pulmonary disease (COPD). The peptide was administered for 1 month following a 60-day exposure to NO2. The results indicated a restoration of bronchial epithelium structure and function, as well as enhanced local immunity markers.
Abstract
On the model of chronic obstructive pulmonary disease, the effect of therapy with low-molecular-weight peptides on restructuring and functional activity of bronchial epithelium for restoring the immune and barrier function of the lungs and prevention of inflammatory process progression was studied. Chronic obstructive pulmonary disease was modeled in rats by 60-day intermittent exposure to NO2. Administration of tetrapeptide Bronchogen for 1 month eliminates symptoms of remodeling of the bronchial epithelium and lung tissue typical of chronic obstructive pulmonary disease (goblet cell hyperplasia, squamous metaplasia, lymphocytic infiltration and emphysema, and restoration of ciliated cells). Enhanced production of secretory IgA, a local immunity marker, attested to normalization of functional activity of bronchial epithelium, while normalization of cell composition and profile of proinflammatory cytokines in the bronchoalveolar space reflected reduction of neutrophilic inflammation.